Search

Displaying results 2811 - 2820 of 10000 in total
  1. Drug

    Oteseconazole

    go.drugbank.com/drugs/DB13055
    ApprovedInvestigational

    [L41635] This drug was approved by the FDA on April 26, 2022.[L41645] … [L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal candidiasis (RVVC).

  2. Drug

    Fluciclovine (18F)

    go.drugbank.com/drugs/DB13146
    ApprovedInvestigational

    [A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049] … [A31384] The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body.

  3. Drug

    Didanosine

    go.drugbank.com/drugs/DB00900
    ApprovedInvestigational

    A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. … Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative

  4. Drug

    Edrophonium

    go.drugbank.com/drugs/DB01010
    Approved

    A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.

    Synonyms: 3-hydroxy-N,N-dimethyl-N-ethylanilinium, N-ethyl-3-hydroxy-N,N-dimethylanilinium
  5. Drug

    Erenumab

    go.drugbank.com/drugs/DB14039
    ApprovedInvestigational

    Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the … Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines

  6. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.

  7. Drug

    Clopidogrel

    go.drugbank.com/drugs/DB00758
    ApprovedInvestigational

    [A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and

  8. Drug

    Phenylbutazone

    go.drugbank.com/drugs/DB00812
    ApprovedVet approvedWithdrawn

    Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticSynonyms: 3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine, 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione
  9. Drug

    Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

    go.drugbank.com/drugs/DB15729
    Investigational

    This is followed by purification and expansion of the cells in vitro. … These AMSCs are multipotent, with the capability of forming different tissues, some of which include bone, muscle, neural, and chondrocyte.

  10. Drug

    Chlorcyclizine

    go.drugbank.com/drugs/DB08936
    Approved

    Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic.

    Mixtures: Notuss-NX